Evaxion Biotech A/S - ADR EVAX

NAS: EVAX | ISIN: US29970R1059 20/10/2025

7,090 USD (+4,42%)

(+4,42%) 20/10/2025

Grafiek Evaxion Biotech A/S - ADR

Grafiek Evaxion Biotech A/S - ADR

1 dag1d 4,42%
1 week1w -9,57%
1 maand1m 132,46%
3 maanden3m 175,88%
6 maanden6m 443,30%
1 jaar1j 179,13%
5 jaar5j -28,31%

Evaxion Biotech A/S - ADR in het nieuws

Toon enkel gratis nieuws

17 oktober 2025 · Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation · Persbericht

17 oktober 2025 · Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 · Persbericht

13 oktober 2025 · Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 · Persbericht

8 oktober 2025 · Evaxion expands AI-Immunology™ platform with automated vaccine design module · Persbericht

3 oktober 2025 · Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting · Persbericht

25 september 2025 · Evaxion out-licenses vaccine candidate EVX-B3 to MSD · Persbericht

27 augustus 2025 · Evaxion to present at several conferences during the second half of 2025 · Persbericht

14 augustus 2025 · Evaxion announces business update and second quarter 2025 financial results · Persbericht

11 augustus 2025 · Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 · Persbericht

25 juli 2025 · Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe